Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity-Reference-Cited by-同舟云学术

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Published:2016-07-19 Issue:20 Volume:22 Page:5130-5140
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Ballard Peter,Yates James W.T.,Yang Zhenfan,Kim Dong-Wan,Yang James Chih-Hsin,Cantarini Mireille,Pickup Kathryn,Jordan Angela,Hickey Mike,Grist Matthew,Box Matthew,Johnström Peter,Varnäs Katarina,Malmquist Jonas,Thress Kenneth S.,Jänne Pasi A.,Cross Darren

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 584 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of brain metastases in non-small-cell lung cancer: high-risk features;CNS Oncology;2024-09-12

2. Treatment Advances in Lung Cancer with Leptomeningeal Metastasis;Current Cancer Drug Targets;2024-09

3. Enhancing intracranial efficacy prediction of osimertinib in non-small cell lung cancer: a novel approach through brain MRI radiomics;Frontiers in Neurology;2024-08-30

4. Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM);Journal of Clinical Oncology;2024-08-10

5. Complete response in a lung adenocarcinoma with pleural metastases initially treated with gefitinib and switched to osimertinib after cerebral oligo-progression with unknown T790M mutation: a case report and review of literature;Journal of Medical Case Reports;2024-08-08